Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy
PLOS Computational Biology · 12.03.2026 · 22 (3) · e1014050
DOI: 10.1371/journal.pcbi.1014050 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 12.03.2026. Verfasst von Rui Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pueraria, Insulin-Like Growth Factor Binding Protein 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The dysregulation of N6-methyladenosine (m 6 A) modification drives progression in non-small cell lung cancer (NSCLC), yet its interplay with traditional medicine-derived therapeutics remains largely unexplored. We propose a novel strategy that integrates m 6 A-based prognostic subtypes with Pueraria pharmacology to identify prognostic markers and therapeutic targets related to m 6 A regulators for NSCLC treatment. Multi-omics clustering of 1,661 NSCLC samples identified three distinct m 6 A modification patterns. Based on these, a robust 19-gene prognostic signature was constructed via Cox regression and validated in the GSE31210 dataset. This risk model significantly correlated with immune infiltration and patient survival. Furthermore, the expression patterns of these genes were validated via single-cell RNA-sequencing (scRNA-seq) and RT-qPCR in NSCLC cell lines. To identify pharmacological interventions, we intersected the m 6 A prognostic signature with 7,333 NSCLC-related genes and 366 Pueraria targets, revealing IGFBP1 as the core therapeutic nexus. Immunohistochemistry confirmed the expression of IGFBP1 in NSCLC tissues. Molecular docking and 100-ns molecular dynamics (MD) simulations confirmed stable binding of Pueraria compounds to IGFBP1, specifically 7,8,4’-trihydroxyisoflavone (binding energy = -8.3 kcal/mol) and genistein (-7.4 kcal/mol). This study establishes IGFBP1 as a therapeutic nexus connecting m 6 A-driven NSCLC progression and the anti-tumor effects of Pueraria. Our RNA-modification-guided pharmacology approach advances the integration of traditional medicines into precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.
ORCID-Profile: Yi-Qing Qu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, R., Hu, D. M., Liu, Y. L., Zhao, W., Zhang, Y. X., & Qu, Y. Q. (2026). Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy. PLOS Computational Biology, 22(3), e1014050. https://doi.org/10.1371/journal.pcbi.1014050
Vancouver
Li R, Hu DM, Liu YL, Zhao W, Zhang YX, Qu YQ. Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy. PLOS Computational Biology. 2026;22(3):e1014050. doi:10.1371/journal.pcbi.1014050
BibTeX
@article{Li2026,
author = {Li, Rui and Hu, Dong-Mei and Liu, Yong-Li and Zhao, Wei and Zhang, Yu-Xin and Qu, Yi-Qing},
title = {Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy},
journal = {PLOS Computational Biology},
year = {2026},
volume = {22},
number = {3},
pages = {e1014050},
doi = {10.1371/journal.pcbi.1014050}
}
EUVIMED